Background

Since December 2019, the newly emerged SARS-CoV-2 virus continues to infect humans and many people died from severe Covid-19 during the last 2 years worldwide. Different approaches are being used for treatment of this infection and its consequences, but limited results have been achieved and new therapeutics are still needed. One of the most interesting biotherapeutics in this era are Nanobodies which have shown very promising results in recent researches.

Scope of review

Here, we have reviewed the potentials of Nanobodies in Covid-19 treatment. We have also discussed the properties of these biotherapeutics that make them very suitable for pulmonary drug delivery, which seems to be very important route of administration in this disease.

Major conclusion

Nanobodies with their special biological and biophysical characteristics and their resistance against harsh manufacturing condition, can be considered as promising, targeted biotherapeutics which can be administered by pulmonary delivery pharmaceutical systems against Covid-19.

General significance

Covid-19 has become a global problem during the last two years and with emerging mutant strains, prophylactic and therapeutic approaches are still highly needed. Nanobodies with their specific properties can be considered as valuable and promising candidates in Covid-19 therapy.

背景

自 2019 年 12 月以来，新出现的 SARS-CoV-2 病毒持续感染人类，过去两年全球有许多人死于严重的 Covid-19。人们正在使用不同的方法来治疗这种感染及其后果，但取得的成果有限，仍然需要新的疗法。这个时代最有趣的生物治疗药物之一是纳米抗体，它在最近的研究中显示出了非常有希望的结果。

审查范围

在这里，我们回顾了纳米抗体在 Covid-19 治疗中的潜力。我们还讨论了这些生物治疗药物的特性，这些特性使它们非常适合肺部药物输送，这似乎是这种疾病非常重要的给药途径。

主要结论

纳米抗体具有特殊的生物学和生物物理特性以及对恶劣制造条件的抵抗力，可以被认为是有前途的靶向生物治疗药物，可以通过肺部递送药物系统来对抗Covid-19。

一般意义

过去两年，Covid-19 已成为一个全球性问题，并且随着突变株的出现，仍然非常需要预防和治疗方法。具有特定特性的纳米抗体可被视为 Covid-19 治疗中有价值且有前途的候选者。